Cargando…
The Future of Lung Cancer Screening: Current Challenges and Research Priorities
Lung cancer is the leading cause of cancer-related deaths worldwide, primarily because most people present when the stage is too advanced to offer any reasonable chance of cure. Over the last two decades, evidence has accumulated to show that early detection of lung cancer, using low-radiation dose...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859535/ https://www.ncbi.nlm.nih.gov/pubmed/35210860 http://dx.doi.org/10.2147/CMAR.S293877 |
_version_ | 1784654482282381312 |
---|---|
author | Burzic, Amna O’Dowd, Emma L Baldwin, David R |
author_facet | Burzic, Amna O’Dowd, Emma L Baldwin, David R |
author_sort | Burzic, Amna |
collection | PubMed |
description | Lung cancer is the leading cause of cancer-related deaths worldwide, primarily because most people present when the stage is too advanced to offer any reasonable chance of cure. Over the last two decades, evidence has accumulated to show that early detection of lung cancer, using low-radiation dose computed tomography, in people at higher risk of the condition reduces their mortality. Many countries are now making progress with implementing programmes, although some have concerns about cost-effectiveness. Lung cancer screening is complex, and many factors influence clinical and cost-effectiveness. It is important to develop strategies to optimise each element of the intervention from selection and participation through optimal scanning, management of findings and treatment. The overall aim is to maximise benefits and minimise harms. Additional integrated interventions must include at least smoking cessation. In this review, we summarize the evidence that has accumulated to guide optimisation of lung cancer screening, discuss the remaining open questions about the best approach and identify potential barriers to successful implementation. |
format | Online Article Text |
id | pubmed-8859535 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-88595352022-02-23 The Future of Lung Cancer Screening: Current Challenges and Research Priorities Burzic, Amna O’Dowd, Emma L Baldwin, David R Cancer Manag Res Review Lung cancer is the leading cause of cancer-related deaths worldwide, primarily because most people present when the stage is too advanced to offer any reasonable chance of cure. Over the last two decades, evidence has accumulated to show that early detection of lung cancer, using low-radiation dose computed tomography, in people at higher risk of the condition reduces their mortality. Many countries are now making progress with implementing programmes, although some have concerns about cost-effectiveness. Lung cancer screening is complex, and many factors influence clinical and cost-effectiveness. It is important to develop strategies to optimise each element of the intervention from selection and participation through optimal scanning, management of findings and treatment. The overall aim is to maximise benefits and minimise harms. Additional integrated interventions must include at least smoking cessation. In this review, we summarize the evidence that has accumulated to guide optimisation of lung cancer screening, discuss the remaining open questions about the best approach and identify potential barriers to successful implementation. Dove 2022-02-16 /pmc/articles/PMC8859535/ /pubmed/35210860 http://dx.doi.org/10.2147/CMAR.S293877 Text en © 2022 Burzic et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Burzic, Amna O’Dowd, Emma L Baldwin, David R The Future of Lung Cancer Screening: Current Challenges and Research Priorities |
title | The Future of Lung Cancer Screening: Current Challenges and Research Priorities |
title_full | The Future of Lung Cancer Screening: Current Challenges and Research Priorities |
title_fullStr | The Future of Lung Cancer Screening: Current Challenges and Research Priorities |
title_full_unstemmed | The Future of Lung Cancer Screening: Current Challenges and Research Priorities |
title_short | The Future of Lung Cancer Screening: Current Challenges and Research Priorities |
title_sort | future of lung cancer screening: current challenges and research priorities |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859535/ https://www.ncbi.nlm.nih.gov/pubmed/35210860 http://dx.doi.org/10.2147/CMAR.S293877 |
work_keys_str_mv | AT burzicamna thefutureoflungcancerscreeningcurrentchallengesandresearchpriorities AT odowdemmal thefutureoflungcancerscreeningcurrentchallengesandresearchpriorities AT baldwindavidr thefutureoflungcancerscreeningcurrentchallengesandresearchpriorities AT burzicamna futureoflungcancerscreeningcurrentchallengesandresearchpriorities AT odowdemmal futureoflungcancerscreeningcurrentchallengesandresearchpriorities AT baldwindavidr futureoflungcancerscreeningcurrentchallengesandresearchpriorities |